Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 75 of 130 entries
View as:

Study of FMT Combined With Nivolumab in Gastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05001360 Org: User:
Start: 10/31/21 End: 11/30/23 Due: 11/30/24

POF Versus FOLFOX Plus IP Paclitaxel in AGC

Phase: N/A Priority: Normal
NCT ID: NCT04155671 Org: User:
Start: 12/01/19 End: 06/30/23 Due: 06/30/24

Phase II Study of Different Doses of Radiotherapy Combined With Sintilimab in the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT06468644 Org: User:
Start: 06/17/24 End: 06/30/27 Due: 06/30/28

EBV-TCR-T（YT-E001）for Patients With EBV-positive Recurrent or Metastatic NPC

Phase: N/A Priority: Normal
NCT ID: NCT03648697 Org: User:
Start: 10/10/18 End: 10/10/21 Due: 10/10/22

Study of the Combination of Apatinib and POF

Phase: N/A Priority: Normal
NCT ID: NCT03707639 Org: User:
Start: 11/30/18 End: 11/30/20 Due: 11/30/21

MRI-based Signatures for Survival Prediction in Cervical Cancer With Radiotherapy

Phase: N/A Priority: Normal
NCT ID: NCT06197126 Org: User:
Start: 01/01/24 End: 12/31/28 Due: 12/31/29

Oncorine (H101) Combined With Tislelizumab and Chemotherapy in Previously Untreated Advanced Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06136910 Org: User:
Start: 05/09/23 End: 12/31/25 Due: 12/31/26

PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Subjects With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT05007145 Org: User:
Start: 08/15/21 End: 08/31/23 Due: 08/31/24

Radiotherapy Combined With TKI and Anti-PD-1 Antibody for Stage IIIA Hepatocellular Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT06061445 Org: User:
Start: 01/09/24 End: 12/31/25 Due: 12/31/26

Second-line Surufatinib Combined With Chemotherapy in Advanced CRC

Phase: N/A Priority: Normal
NCT ID: NCT04734249 Org: User:
Start: 03/31/21 End: 12/31/23 Due: 12/31/24

POF Versus FOLFOX Versus FOLFOX Plus ip Paclitaxel in AGC

Phase: N/A Priority: Normal
NCT ID: NCT02845908 Org: User:
Start: 11/30/15 End: 05/31/20 Due: 05/31/21

Toripalimab as Maintenance Therapy in Patients With Driver-gene Negative Advanced NSCLC After First-line Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT04613804 Org: User:
Start: 12/01/20 End: 11/30/23 Due: 11/30/24

To Determine the Efficacy and Safety of Envafolimab Combined With XELOX for Locally Advanced Colon Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05335460 Org: User:
Start: 05/31/22 End: 05/31/24 Due: 05/31/25

Recombinant Human Adenovirus Type 5 Injection Combined With PD-1 Monoclonal Antibody and Nab-paclitaxel in the Treatment of Patients With Liver Metastases From Malignant Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT05664139 Org: User:
Start: 02/28/23 End: 12/31/25 Due: 12/31/26

Gefitinib and Berberine in the First-line Treatment of Lung Adenocarcinoma With EGFR Mutation

Phase: N/A Priority: Normal
NCT ID: NCT03486496 Org: User:
Start: 06/05/18 End: 02/01/20 Due: 02/01/21

Effects of Anesthesia on Tumor Immunity and Insulin Resistance During Perioperative Period

Phase: N/A Priority: Normal
NCT ID: NCT03872635 Org: User:
Start: 01/01/18 End: 12/31/18 Due: 12/31/19

Surufatinib Combined With Sintilimab for Advanced MSS-Type Colorectal Cancer : a Phase II Study

Phase: N/A Priority: Normal
NCT ID: NCT04764006 Org: User:
Start: 10/13/21 End: 11/01/23 Due: 11/01/24

Short-term Outcomes of SILS+1 Versus CLS for Distal Gastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05035446 Org: User:
Start: 10/01/21 End: 08/31/22 Due: 08/31/23

EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT03720873 Org: User:
Start: 10/31/18 End: 09/30/22 Due: 09/30/23

Triprilimab(JS001) and Chemotherapy Combined With Local Treatment for Multiple Metastatic NPC

Phase: N/A Priority: Normal
NCT ID: NCT04421469 Org: User:
Start: 06/15/20 End: 06/15/23 Due: 06/15/24

EGFR-TKIs Combine Chemotherapy as First-line Therapy for Patients With Advanced EGFR Mutation-positive NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT02886195 Org: User:
Start: 07/31/16 End: 07/31/19 Due: 07/31/20

Using Mini Program for Self-management VS Conventional Pharmaceutical Care for Cancer Pain

Phase: N/A Priority: Normal
NCT ID: NCT04844645 Org: User:
Start: 05/01/21 End: 06/01/21 Due: 06/01/22

Next-generation Sequencing in Gastrointestinal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03476057 Org: User:
Start: 07/01/18 End: 12/31/20 Due: 12/31/21

Elective Level Ib Irradiation in Nasopharyngeal Carcinoma Patients Based on the International Guidelines

Phase: N/A Priority: Normal
NCT ID: NCT05519956 Org: User:
Start: 09/16/22 End: 09/30/25 Due: 09/30/26

EGFR Mutation Positive NSCLC Patients With Gefitinib and Thalidomide

Phase: N/A Priority: Normal
NCT ID: NCT03341494 Org: User:
Start: 04/01/17 End: 11/01/20 Due: 11/01/21